Table 4 Clinical comparisons between HCC (−) and HCC ( + groups at 48 weeks after start of NA therapy in Study 2.

From: Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy

 

HCC (−) (n = 43)

HCC ( +) (n = 8)

P-value

 

Median (IQR)

  

Age, years

47 (41–61)

67 (59–73)

0.001

Male, n (%)

21 (48.8%)

6 (75.0%)

0.255

PLT, × 104/µL

19.6 (16.6–24.6)

11.6 (8.6–15.1)

0.001

Alb, g/dL

4.2 (3.9–4.5)

4.1 (3.7–4.2)

0.262

T. Bil, mg/dL

0.75 (0.51–0.95)

1.01 (0.67–1.35)

0.133

AST, U/L

29 (18–23)

25 (23–35)

0.204

ALT, U/L

17 (14–23)

18 (14–30)

0.775

TSP2, ng/mL

23.5 (19.6–32.6)

32.2 (28.5–40.8)

0.043

HBsAg, log IU/mL

3.40 (2.70–3.75)

2.73 (1.52–3.22)

0.042

HBeAg ( +), n (%)

15 (34.9%)

1 (12.5%)

0.409

HBV-DNA, log IU/mL

N/D (N/D-N/D)

N/D (N/D-1.6)

0.685

  1. Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IQR, interquartile range; NA, nucleos(t)ide analog; N/D, not detected; PLT, platelet count; T. Bil, total bilirubin; TSP2, thrombospondin 2.
Back to article page